2013•Chinese Journal of Modern Drug ApplicationRequires access

Analysis of treatment efficacy of cyclosporine A combined with human recombinant interleukin-11 in refractory immune thrombocytopenic purpura

Yang Guo-le

Abstract

Objective To discuss the treatment efficacy of cyclosporine A( CSA) combined with human recombinant interleukin-11( IL-11) in refractory immune thrombocytopenic purpura. Methods All 37patients diagnosed as refractory immune thrombocytopenic purpura were divided into observation group and control group. Observation group: IL-11 [30 μg /( kg · d) ] and CSA [5 mg /( kg · d) ] were added. Control group: only CSA [5 mg /( kg·d) ] was added. The observation time was six months. Results The effective rates were 91% and 63% in Observation group and Control group,respectively. The difference was significant( P 0. 05). Conclusion CSA combined with IL-11 had good treatment efficacy and security in refractory immune thrombocytopenic purpura.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Thrombocytopenic purpura, Refractory (planetary science), Immune system, Medicine, Recombinant DNA, Immunology, Purpura (gastropod), Gastroenterology